Market Research Report
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
|Published by||La Merie Publishing||Product code||146105|
|Published||Content info||301 Pages
|Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors|
|Published: May 1, 2013||Content info: 301 Pages||
The new Competitive Intelligence Report ‘Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors of May 2013’ provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:
Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.
With more than US$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.
This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.
Competitor projects are listed in a tabular format providing Information on:
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Next generation biologic Eythropoiesis Stimulating Agents (ESA)
in regulated markets - IV